FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115370139> ?p ?o ?g. }

• W3115370139 endingPage "48" @default.
• W3115370139 startingPage "39" @default.
• W3115370139 abstract "Diversos estudios de prevención primaria y secundaria han documentado que un mayor grado de reducción en los niveles de colesterol unido a proteínas de baja densidad (cLDL) se asocia a una mayor disminución en las tasas de eventos cardiovasculares. Los inhibidores de la PCSK9 logran disminuciones importantes, rápidas y mantenidas en los niveles de cLDL. Las nuevas guías de práctica clínica sobre dislipemias establecen unos nuevos niveles objetivo de cLDL muy reducidos en los pacientes que presentan un riesgo cardiovascular muy elevado. Estos objetivos son difícilmente alcanzables con un tratamiento basado únicamente en estatinas, incluso en combinación con ezetimiba. La adición de inhibidores de la PCSK9 puede tener un papel determinante para alcanzar estas recomendaciones. Sin embargo, es importante identificar los subgrupos de pacientes que más se pueden beneficiar de esta marcada reducción en los niveles lipídicos. En el presente documento se describen los perfiles de pacientes en los que la máxima disminución en los niveles de cLDL debe constituir un objetivo prioritario, y se plantean las estrategias para facilitar el uso juicioso de estos nuevos fármacos. Different primary and secondary prevention studies have documented that a greater degree of reduction in low-density lipoprotein cholesterol (LDL-C) levels is associated with a greater decrease in cardiovascular event rates. PCSK9 inhibitors achieve important, rapid and sustained decreases in LDL-C. New clinical practice guidelines for the management of dyslipidemia establish reduced target levels of LDL-C. These goals are hardly achievable with a statin-only treatment, even in combination with ezetimibe. The addition of PCSK9 inhibitors can play a determining role in achieving these recommendations. However, it is important to identify the patient subgroups that can most benefit from this marked reduction in LDL-C levels. This document describes the profiles of patients with cardiovascular disease in which the maximum decrease in LDL-C levels should be a priority objective, considering strategies to achieve these levels and to facilitate the judicious use of these new drugs." @default.
• W3115370139 created "2021-01-05" @default.
• W3115370139 creator A5000996407 @default.
• W3115370139 creator A5003061525 @default.
• W3115370139 creator A5004444515 @default.
• W3115370139 creator A5015362609 @default.
• W3115370139 creator A5020780282 @default.
• W3115370139 creator A5022345890 @default.
• W3115370139 creator A5033111261 @default.
• W3115370139 creator A5036786740 @default.
• W3115370139 creator A5036968408 @default.
• W3115370139 creator A5039483633 @default.
• W3115370139 creator A5051369406 @default.
• W3115370139 creator A5051602839 @default.
• W3115370139 creator A5054818441 @default.
• W3115370139 creator A5064942145 @default.
• W3115370139 creator A5082038454 @default.
• W3115370139 creator A5091685133 @default.
• W3115370139 creator A5089848514 @default.
• W3115370139 date "2021-01-01" @default.
• W3115370139 modified "2023-10-16" @default.
• W3115370139 title "Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica" @default.
• W3115370139 cites W1520609538 @default.
• W3115370139 cites W1908289777 @default.
• W3115370139 cites W199262836 @default.
• W3115370139 cites W2024930123 @default.
• W3115370139 cites W2111099202 @default.
• W3115370139 cites W2261871796 @default.
• W3115370139 cites W2300419386 @default.
• W3115370139 cites W2329832047 @default.
• W3115370139 cites W2352723316 @default.
• W3115370139 cites W2465758073 @default.
• W3115370139 cites W2495429586 @default.
• W3115370139 cites W2588614813 @default.
• W3115370139 cites W2596179513 @default.
• W3115370139 cites W2602580500 @default.
• W3115370139 cites W2744116768 @default.
• W3115370139 cites W2746224452 @default.
• W3115370139 cites W2748800769 @default.
• W3115370139 cites W2754562397 @default.
• W3115370139 cites W2768555410 @default.
• W3115370139 cites W2768588165 @default.
• W3115370139 cites W2784509123 @default.
• W3115370139 cites W2791615591 @default.
• W3115370139 cites W2810168964 @default.
• W3115370139 cites W2829641613 @default.
• W3115370139 cites W2888390078 @default.
• W3115370139 cites W2888613170 @default.
• W3115370139 cites W2889582862 @default.
• W3115370139 cites W2894417323 @default.
• W3115370139 cites W2899997727 @default.
• W3115370139 cites W2900103074 @default.
• W3115370139 cites W2902436102 @default.
• W3115370139 cites W2940327706 @default.
• W3115370139 cites W2949589992 @default.
• W3115370139 cites W2954453953 @default.
• W3115370139 cites W2963429759 @default.
• W3115370139 cites W2970851438 @default.
• W3115370139 cites W2971715820 @default.
• W3115370139 cites W2973253443 @default.
• W3115370139 cites W2976144989 @default.
• W3115370139 cites W3183857127 @default.
• W3115370139 doi "https://doi.org/10.1016/j.rccl.2020.10.017" @default.
• W3115370139 hasPublicationYear "2021" @default.
• W3115370139 type Work @default.
• W3115370139 sameAs 3115370139 @default.
• W3115370139 citedByCount "5" @default.
• W3115370139 countsByYear W31153701392021 @default.
• W3115370139 countsByYear W31153701392022 @default.
• W3115370139 crossrefType "journal-article" @default.
• W3115370139 hasAuthorship W3115370139A5000996407 @default.
• W3115370139 hasAuthorship W3115370139A5003061525 @default.
• W3115370139 hasAuthorship W3115370139A5004444515 @default.
• W3115370139 hasAuthorship W3115370139A5015362609 @default.
• W3115370139 hasAuthorship W3115370139A5020780282 @default.
• W3115370139 hasAuthorship W3115370139A5022345890 @default.
• W3115370139 hasAuthorship W3115370139A5033111261 @default.
• W3115370139 hasAuthorship W3115370139A5036786740 @default.
• W3115370139 hasAuthorship W3115370139A5036968408 @default.
• W3115370139 hasAuthorship W3115370139A5039483633 @default.
• W3115370139 hasAuthorship W3115370139A5051369406 @default.
• W3115370139 hasAuthorship W3115370139A5051602839 @default.
• W3115370139 hasAuthorship W3115370139A5054818441 @default.
• W3115370139 hasAuthorship W3115370139A5064942145 @default.
• W3115370139 hasAuthorship W3115370139A5082038454 @default.
• W3115370139 hasAuthorship W3115370139A5089848514 @default.
• W3115370139 hasAuthorship W3115370139A5091685133 @default.
• W3115370139 hasConcept C126322002 @default.
• W3115370139 hasConcept C138885662 @default.
• W3115370139 hasConcept C15708023 @default.
• W3115370139 hasConcept C2778096610 @default.
• W3115370139 hasConcept C2779134260 @default.
• W3115370139 hasConcept C2993857929 @default.
• W3115370139 hasConcept C71924100 @default.
• W3115370139 hasConceptScore W3115370139C126322002 @default.
• W3115370139 hasConceptScore W3115370139C138885662 @default.
• W3115370139 hasConceptScore W3115370139C15708023 @default.
• W3115370139 hasConceptScore W3115370139C2778096610 @default.

• next